Soft tissue sarcoma · 4 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Pembrolizumab and RT Variant #01 | — | R 327 949 | — | — | — | ~3 | ~R 491 923 indirect | — |
Epirubicin and Ifosfamide Variant #03 | — | R 27 949 | 21d | — | — | ~7 | ~R 195 643 indirect | — |
EIA Variant #01 | — | R 15 103 | 21d | — | — | ~4 | ~R 60 413 indirect | — |
No neoadjuvant therapy Partial | — | — | — | ~26.4 mo | ~37.0 mo | — | — | 12 |
4 of 4 regimens shown